CCN5 activation by free or encapsulated EGCG is required to render triple‐negative breast cancer cell viability and tumor progression

CCN5 activation by free or encapsulated EGCG is required to render triple‐negative breast cancer cell viability and tumor progression

Abstract Epigallocatechin‐3‐gallate (EGCG) has been considered an anticancer agent despite conflicting and discrepant bioavailability views. EGCG impairs the viability and self‐renewal capacity of triple‐negative breast cancer (TNBC) cells and makes them sensitive to estrogen via activating ER‐α. Su...

Full description

Bibliographic Details
Main Authors: Amlan Das, Inamul Haque, Priyanka Ray, Arnab Ghosh, Debasmita Dutta, Mohiuddin Quadir, Archana De, Sumedha Gunewardena, Indranil Chatterjee, Snigdha Banerjee, Scott Weir, Sushanta K. Banerjee
Format: Article
Language:English
Published: Wiley 2021-04-01
Series:Pharmacology Research & Perspectives
Subjects:
bioavailability
breast cancer
CCN5
drug delivery
EGCG
FA‐PEG‐NPs
Online Access:https://doi.org/10.1002/prp2.753

Internet

https://doi.org/10.1002/prp2.753

Similar Items